CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to improve treatment for glioblastoma multiforme by combining temozolomide with NO-releasing compounds to overcome drug resistance. It also involves developing an injectable hydrogel for targeted delivery, enhancing drug efficacy and reducing tumor recurrence.
Glioblastoma multiforme (GBM) is a grade IV glioma, considered as the most aggressive brain tumor with an average five-year survival rate of 7.2% and projected mortality rate of 46.6% by 2040.
The prognosis remains poor, not only due to the severity of the disease but also due to challenges in treatment modality and recurrence.
Temozolomide (TMZ) is the preferred anticancer drug for GBM owing to its effectiveness in reducing relapse but the efficacy is compromised by substantial hurdle of drug r…
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Nottingham
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
